All Companies articles – Page 11
-
ArticleAACR 2025: translating research into real-world impact
From first-in-human trial results to emerging AI tools and patient-focused innovations, AACR 2025 offered a clear snapshot of where cancer research is heading. Drug Target Review was on the ground in Chicago to explore the clinical data, technologies, and conversations shaping cancer drug development.
-
ArticleBuilding the requisite clinical development infrastructure for medical innovation to thrive
Outdated clinical development systems are slowing breakthroughs like gene therapies and precision medicine. This article explores how a flexible, on-demand approach can accelerate drug development and bring innovations to patients faster.
-
ArticleUsing knowledge graphs in drug discovery (Part 2): how they’re shaping scientific progress
In this second interview of the series, Andreas Kolleger, Head of GenAI Innovation at Neo4j, discusses how knowledge graphs and AI are transforming scientific discovery and improving life sciences workflows.
-
ArticleAI in drug discovery: faster, smarter, better
Claudia Zylberberg, Chair of Kosten Digital, reveals how AI is revolutionising cell and gene therapy, making drug discovery faster and more cost-effective.
-
ReportBeyond the Lab: Clinical Trials
Explore how artificial intelligence (AI), biomarkers, and innovative trial technologies are creating a more efficient, data-driven future for drug discovery. From better patient selection to smarter trial design, see how clinical research is evolving to deliver new therapies faster.
-
ArticleBuilding better drugs: how 3D models are shaping pre-clinical development
Three-dimensional (3D) models are reshaping pre-clinical drug development by providing more accurate insights into drug safety and efficacy. Explore how these advanced in vitro systems help improve predictions and reduce the risk of failure in early-stage drug discovery.
-
ArticleNext-gen ADCs: Tubulis sets new standard in cancer treatment
Tubulis, led by CEO Dominik Schumacher, is advancing cancer treatment through next-generation antibody-drug conjugates (ADCs) designed to target solid tumours more effectively. Find out how the company is rapidly progressing its ADC pipeline to offer more precise and lasting treatment options for patients.
-
ArticleAI-powered imaging for faster lung disease treatment
Deep learning is transforming lung disease treatment by enabling earlier diagnosis, precise monitoring and more efficient clinical trials. This article explores how AI-driven imaging is accelerating drug development and improving patient outcomes.
-
ArticleLB-102: Redefining schizophrenia treatment in drug discovery
Find out how LB Pharmaceuticals' LB-102 is advancing schizophrenia treatment. This first-in-class antipsychotic demonstrates strong efficacy, safety and tolerability, potentially addressing both acute and negative symptoms. Explore its potential impact on neuropsychiatric drug discovery.
-
ArticlePioneering cellular therapies for age-related diseases
Discover how Immorta Bio's cellular therapies are addressing cancer and liver failure, with the potential to transform healthcare.
-
NewsBacteria-boosted nanoparticles offer a triple threat against cancer
A new cancer therapy combines multiple treatment strategies into a single graphene oxide-based nanocomposite. It uses bacterial components to enhance immune response and scalability, creating a powerful and cost-effective approach to tackling tumours.
-
NewsNew leadership at ELRIG aims to expand collaboration across drug discovery
ELRIG, a UK-based scientific community driving innovation in drug discovery, has appointed biopharma leader Dr Del Trezise as its new Chair - signalling a bold new chapter for the organisation.
-
ArticleSpirulina’s role in shaping the future of preventative biologics
From law to biotech, Brian Finrow's career path has been anything but conventional. As Co-founder and CEO of Lumen Bioscience, he’s steering the company’s innovative approach to drug discovery, focusing on preventative biologics that offer scalable, cost-effective solutions. Find out how Finrow's unique spirulina-based platform is changing the way we ...
-
ArticleEarly evidence and emerging trends: How AI is shaping drug discovery and clinical development
Drug development is plagued by high costs, long timelines and low success rates, but what if AI could change that? Read on to discover real-world examples and explore the transformative potential of AI in drug development.
-
ArticleGylden’s gold platform trains T cells to kill viruses
What if vaccines could train your immune system to eliminate infections at the source? Find out how Gylden Pharma’s gold nanoparticle platform delivers targeted T cell immunity - providing a precise and durable defence against complex infectious diseases.
-
WebinarAdvancing ADC Development: End-to-End Solutions from Design to Characterization
Dr. Francisca Neethling from Eurofins Discovery explores the comprehensive process of ADC development, covering payload linker design, optimization, and the bioanalytical and functional characterization of ADC molecules.
-
ArticleNext-gen biotech: rBIO’s approach to affordable insulin solutions
rBIO is transforming the biosimilar insulin market with a novel biomanufacturing platform designed to reduce production costs while maintaining high-quality standards. CEO Cameron Owen shares how their approach is shaping drug discovery and improving patient access to life-saving treatments.
-
ArticleGene silencing: a step forward for rare disease therapy
Gene silencing offers a promising approach to treating rare neurological diseases like H-ABC. With clinical trials on the horizon, find out how targeted therapies could bring real hope to patients and families.
-
ArticleABB’s robotics ecosystem: advancing lab efficiency in drug discovery
In this interview with Jose-Manuel Collados, learn how ABB's strategic partnerships and automation technology are improving lab efficiency, enhancing precision and ultimately speeding up the development of life-saving treatments.
-
ArticleNew advances in hormone replacement therapy set to transform care
Hormone replacement therapy has long been used to treat low hormone levels, but existing delivery methods struggle with poor adherence and inconsistent hormone delivery. Lisa Stehno-Bittel of Likarda and Charles Virden of VitalTE discuss a novel approach using hormone-filled microbeads in hydrogels for steady, extended release after monthly self-injections.